Novartis to Acquire Experimental Breast Cancer Drug in $3 Billion Deal

Novartis has announced an agreement to purchase an experimental breast cancer drug for up to $3 billion. Bloomberg posted on X, highlighting the pharmaceutical giant's strategic move to expand its oncology portfolio. The acquisition underscores Novartis's commitment to advancing cancer treatment options and enhancing its position in the competitive pharmaceutical market. The deal reflects the company's focus on innovative therapies that address unmet medical needs in the field of oncology. Further details about the transaction and the specific drug involved have not been disclosed.